Back to Agenda
Session 6: Innovative Business Models For Pediatric Therapeutic Development
Session Chair(s)
Thomas Miller, PHD
Vice President and Global Head, Pediatrics, Bayer, United States
Christina Bucci-Rechtweg, MD
Global Head, Maternal Health and Pediatric Regulatory Policy, Novartis , United States
In recent years, deliberate prioritization of medication development for children has accelerated broadly across the life sciences ecosystem. This session will explore evolving, innovative business models for pediatric therapeutics. Presentations will focus on the increasingly important role of key stakeholders including large pharma, venture capital, and new academic medical center business models relating to pediatric therapeutics development. Presentations will be followed by an engaging panel discussion.
Learning Objective : At the conclusion of this session, participants should be able to:- Gain the growing role of pediatric therapeutics development in the life sciences ecosystem
- Understand how companies make decisions regarding inclusion of pediatric development programs within their portfolios
- Understand the unique, evolving and important roles of large Pharma, Venture Capital, and Academic Institutions play towards the advancement of new medications for children
Speaker(s)
Thomas Miller, PHD
Vice President and Global Head, Pediatrics, Bayer, United States
Pharma Portfolio Considerations for Pediatric Development Programs
Gavin Miyasato, MS
Associate Director of Statistics , TRINITY, United States
TRINITY Whitepaper: What We Value – the Proposition Behind the Price
Daniel Fields, JD
Vice President, Business Innovation, Children’s Hospital of Philadelphia, United States
Redefining the Approach for Pediatric Academic Medical Centers
Have an account?